Keros Therapeutics, Inc.

Keros Therapeutics (KROS) shows no cyber incidents or red-flag 8-K filings in our 90-day monitoring window, suggesting operational stability on those fronts. However, a clean near-term record does not preclude structural risks common to clinical-stage biotech—equity dilution cycles, financing dependency, and pipeline-dependent valuation volatility remain material. Our 90-day snapshot is necessarily narrow; The full $49 Report adds 12-month event history, dilution risk scoring, detailed financing trajectory, and AI-driven risk signals across cash runway and capital structure dynamics.